Market
What will be Stryker's strategy for integrating Inari's products by March 31, 2025?
2
Resolution / Starting Odds
Full Integration • 25%
Partial Integration • 25%
Independent Operation • 25%
Discontinued Products • 25%
Company announcements, press releases, or financial reports
Story
Stryker to Acquire Inari Medical for $4.9 Billion at $80 Per Share, Targeting VTE Treatments
Jan 6, 2025, 08:22 PM
Stryker Corp. has announced a definitive agreement to acquire Inari Medical, Inc. for $80 per share in cash, valuing the deal at approximately $4.9 billion. The acquisition aims to expand Stryker's portfolio into the high-growth peripheral vascular segment, particularly targeting venous thromboembolism (VTE) treatments. Inari's innovative product offerings, which include mechanical thrombectomy solutions for conditions like deep vein thrombosis and pulmonary embolism, are seen as complementary to Stryker's existing Neurovascular business. The transaction is expected to close by the end of the first quarter of 2025, pending customary closing conditions including regulatory approvals.
View original story
Similar markets
Less than 5% • 25%
More than 15% • 25%
10-15% • 25%
5-10% • 25%
Yes • 50%
No • 50%
5 or more • 25%
None • 25%
3-4 • 25%
1-2 • 25%
No significant changes • 25%
Expansion into new markets • 25%
Focus on existing products • 25%
Development of new products • 25%
Market expansion • 25%
Other • 25%
Research and development • 25%
Enhancing avatar realism • 25%
Successful acquisition of another biotech • 25%
Successful acquisition of Sage Therapeutics • 25%
Multiple acquisitions completed • 25%
No acquisitions completed • 25%
Increase by 1-5% • 25%
Decrease • 25%
No significant change • 25%
Increase by more than 5% • 25%
